Trials / Completed
CompletedNCT00111644
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
A Randomized, Double-blind Study of the Effect of Beta-lactam on Treatment Response in Patients Hospitalized With Bacterial Pneumonia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 302 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of intravenous beta-lactam, in comparison with ceftriaxone, in hospitalized patients with community-acquired pneumonia not caused by Legionella. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ceftriaxone | 1000mg iv daily |
| DRUG | beta-lactam | 750mg iv q 23h for 3-14 days |
| DRUG | beta-lactam | 1500mg iv q 12h for 3-14 days |
Timeline
- Start date
- 2005-03-01
- Primary completion
- 2007-01-01
- Completion
- 2007-01-01
- First posted
- 2005-05-25
- Last updated
- 2016-11-02
Locations
49 sites across 11 countries: United States, Argentina, Bulgaria, Chile, Croatia, Hungary, Latvia, Lithuania, Peru, Romania, Slovakia
Source: ClinicalTrials.gov record NCT00111644. Inclusion in this directory is not an endorsement.